IPP Bureau
Zydus receives USFDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets
By IPP Bureau - November 09, 2022
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Sun Pharmaceutical gets OAI from USFDA for Mohali facility
By IPP Bureau - November 09, 2022
Piramal Phamra reports Q2 FY23 consolidated loss at Rs. 37.34 Cr
By IPP Bureau - November 09, 2022
Ami Organics Q2 FY23 revenue up 20.2%; Profit up 9%
By IPP Bureau - November 08, 2022
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr
By IPP Bureau - November 08, 2022
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
SeQuent Scientific to acquire 100% stake in Tineta Pharma
By IPP Bureau - November 08, 2022
The acquisition is for an enterprise value of Rs. 218 crores
Apollo Hospital launches Vertigo and Balance Disorder clinic in Hyderabad
By IPP Bureau - November 08, 2022
Zydus receives EIR with VAI from USFDA for Moraiya facility
By IPP Bureau - November 08, 2022
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%
By IPP Bureau - November 07, 2022
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe
By IPP Bureau - November 07, 2022
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
By IPP Bureau - November 07, 2022
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Lupin receives tentative approval from USFDA for Drospirenone Tablets
By IPP Bureau - November 07, 2022
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression
By IPP Bureau - November 07, 2022
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
By IPP Bureau - November 07, 2022
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Zydus Announces New Data Presentations at The Liver Meeting 2022
By IPP Bureau - November 04, 2022
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
